The recommended starting dosage of tirzepatide is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.1

After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.1

The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose.1

The recommended maintenance dosages of tirzepatide in adults are 5, 10, or 15 mg injected subcutaneously once weekly.1

Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.1 

The maximum dosage of tirzepatide is 15 mg injected subcutaneously once weekly.1

Administer in combination with a reduced-calorie diet and increase physical activity.1

Administer tirzepatide

• once weekly
• any time of day, and
• with or without food.1

The global phase 3 SURMOUNT clinical program for weight management evaluated tirzepatide 5, 10, 15 mg, and maximum tolerated dosages for safety and efficacy. These doses and associated dose-escalation schemes (Dose Escalation Schedule for Tirzepatide in Phase 3 Clinical Studies) were based on the assessment of safety, efficacy (weight loss), and GI tolerability data in phase 1 and 2 studies in patients with T2DM, followed by exposure-response modeling of the data that predicted weight loss in patients with overweight or obesity.2

The SURMOUNT-OSA master protocol described two 52-week, phase 3, double-blind, randomized studies of tirzepatide maximum tolerated dose (MTD) (10 or 15 mg) once weekly compared with placebo in 469 adults with moderate to severe OSA and obesity. Both of these OSA studies followed the same dosage escalation scheme that was used in the clinical development program for weight management.3